The FDA cleared the investigational new drug application for REC-4539, allowing for the start of a phase 1/2 trial in small ...

PD-L1 not only responds to the cGAS-STING pathway upon DNA damage, but also regulates cGAS-STING to induce inflammation. This ...

Io Therapeutics Inc. has presented new preclinical data on their RARγ agonist IRX-5010 for the treatment of triple-negative ...

Sensei Biotherapeutics (SNSE) provided corporate updates on its lead program, solnerstotug and upcoming milestones. Key findings and updates as ...

BeiGene (NASDAQ:BGNE) announced Friday that the U.S. Food and Drug Administration (FDA) approved its cancer medicine Tevimbra ...

Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.

Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung cancer reaches ...

INR:6268. asia cup 2022 teams list CStone Pharmaceuticals' anti-PD-L1 study data in patients with esophageal squamous cell carcinoma are positive The ant ...

Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update ...